# QT Interval Effects Study of Oral FXS5626 Tablets

> **NCT07695779** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 28 (estimated)

## Conditions studied

- Evaluation of QTc Interval

## Interventions

- **DRUG:** FXS5626 tablet
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT07695779
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-05
- **Primary completion:** 2026-09-25
- **Final completion:** 2026-09-25
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07695779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07695779, "QT Interval Effects Study of Oral FXS5626 Tablets". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07695779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*